Trenbolone
Also known as: Tren, Tren A, Tren E, Trenbolone Acetate, Trenbolone Enanthate, Finaplix, Parabolan, Trenbolone Hexahydrobenzylcarbonate
19-Nor Anabolic-Androgenic Steroid | Potent Recomposition Agent
Overview
Trenbolone is a synthetic 19-nortestosterone derivative and one of the most potent anabolic-androgenic steroids in common use. Originally developed for veterinary applications -- specifically as the implant pellet product Finaplix for increasing feed efficiency and lean mass in cattle -- trenbolone has never been approved for human medical use. The sole exception was a brief period in the 1980s and 1990s when trenbolone hexahydrobenzylcarbonate was marketed as Parabolan in France for human clinical use, primarily for muscle wasting and cachexia, before being voluntarily discontinued. Trenbolone's pharmacological profile is remarkable: it exhibits approximately five times the anabolic and androgenic potency of testosterone, reflected in its anabolic:androgenic ratio of 500:500 compared to testosterone's 100:100. This extraordinary potency stems from three conjugated double bonds in its steroid nucleus that dramatically enhance androgen receptor binding affinity. Unlike its parent compound nandrolone, trenbolone does not aromatize to estrogen, which contributes to its pronounced ability to produce lean, dry gains without significant water retention. However, trenbolone does exhibit significant progestogenic activity, which can elevate prolactin levels and produce a distinct set of side effects unrelated to estrogen. Trenbolone is widely regarded as the most powerful commonly available anabolic steroid for body recomposition -- simultaneously building muscle while reducing body fat. This reputation comes at a considerable cost: trenbolone carries one of the harshest side effect profiles of any steroid, including insomnia, night sweats, cardiovascular strain, respiratory distress upon injection (tren cough), anxiety, and aggression. It is strictly an advanced-only compound that should never be used by beginners or individuals without extensive experience managing anabolic steroid cycles and their ancillary requirements.
Key benefits
- Exceptional lean muscle mass accrual with minimal water retention due to non-aromatizing profile
- Dramatic body recomposition capability -- simultaneous muscle gain and fat loss even in caloric deficit
- Approximately five times the anabolic and androgenic potency of testosterone (500:500 ratio)
- Powerful anti-catabolic effects through glucocorticoid receptor antagonism, protecting muscle during dieting
- Significant increases in strength across all compound movements, often rapid in onset
- Enhanced nutrient partitioning, directing calories toward lean tissue accretion over fat storage
- Pronounced muscle hardness, density, and vascularity due to absence of estrogenic water retention
- Increased IGF-1 production in muscle tissue, amplifying growth signaling pathways
Mechanism of action
Trenbolone binds to the androgen receptor with approximately three to five times the affinity of testosterone, making it one of the strongest known AR agonists among anabolic steroids. This exceptional binding affinity drives potent activation of AR-dependent gene transcription, resulting in dramatically enhanced nitrogen retention, protein synthesis, and satellite cell proliferation in skeletal muscle. Trenbolone also powerfully inhibits glucocorticoid receptors, reducing cortisol-mediated catabolism and shifting the body's metabolic environment decisively toward anabolism even during caloric restriction -- a property central to its reputation as a recomposition agent. The compound significantly increases IGF-1 expression in muscle tissue, further amplifying its anabolic signaling cascade. A distinguishing feature of trenbolone is its complete resistance to aromatization. The conjugated double bond system in the A-ring prevents interaction with the aromatase enzyme, meaning trenbolone produces no estrogenic metabolites. This eliminates estrogen-mediated water retention and fat deposition but does not protect against gynecomastia, because trenbolone activates progesterone receptors at meaningful affinity. Progesterone receptor activation can sensitize breast tissue to circulating estrogen (from a concurrent testosterone base) and independently elevate prolactin levels, potentially causing lactation, sexual dysfunction, and mood disturbance. Trenbolone also strongly increases nutrient partitioning efficiency, directing calories preferentially toward muscle protein synthesis rather than adipose storage. This effect, originally exploited in cattle feed lots to produce leaner beef, translates to the dramatic body recomposition effects observed in human users. Unlike nandrolone, trenbolone is not meaningfully metabolized by 5-alpha reductase. In fact, 5-alpha reductase inhibitors like finasteride do not reduce trenbolone's androgenic activity and can paradoxically worsen androgenic side effects, because trenbolone's own metabolites (produced through different enzymatic pathways) are more androgenic than the parent compound in certain tissues. Trenbolone's impact on the cardiovascular system is notably severe: it reduces HDL cholesterol, increases LDL cholesterol, promotes left ventricular hypertrophy, and may directly damage cardiac tissue through mechanisms independent of its effects on lipids.
Molecular data
- Type
- 19-nortestosterone derivative (C18H22O2), trienone steroid
- Half-life
- ~3 days (acetate)
Indications
What the research community uses this compound for, with self-reported effectiveness.
Body Composition
Strength Performance
Veterinary
Dosing protocols
Common protocols by delivery method. Adjust the curve below to model accumulation in your own cycle.
Delivery method
| Protocol | Dose | Frequency | Duration |
|---|---|---|---|
| — | 200-300 mg/week (50-75 mg every other day) | Every other day | — |
| — | 300-400 mg/week (75-100 mg every other day) | Every other day | — |
| — | 200-400 mg/week | 2x per week | — |
| — | 300-500 mg/week | Every other day (acetate) or 2x per week (enanthate) | — |
Protocol variations
Alternative cycling patterns reported in the literature and community.
Trenbolone Acetate
Trenbolone acetate is the gold standard ester for this compound. Originally sourced from Finaplix cattle implant pellets (which were converted into injectable preparations), pharmaceutical-grade acetate is now produced by numerous underground laboratories. The short ester chain provides rapid onset of action, with peak blood levels reached within 24-48 hours of injection. The most significant practical advantage is manageability: because the ester clears quickly, users who experience intolerable side effects -- severe insomnia, extreme anxiety, cardiovascular distress -- can discontinue and expect meaningful symptom resolution within 5-7 days. This quick-exit option is not available with longer esters.
Trenbolone Enanthate
Trenbolone enanthate attaches the same long-chain ester used on testosterone enanthate, extending the half-life to approximately 10-14 days. This allows for twice-weekly injections and more stable blood levels with fewer peaks and troughs. However, the extended half-life is a double-edged sword: while it offers convenience, it means that if a user experiences severe side effects, the compound remains active in the body for weeks after the last injection. For this reason, trenbolone enanthate is recommended only for users who have prior experience with trenbolone acetate and have confirmed they tolerate the compound acceptably. Trenbolone enanthate has never been manufactured by any pharmaceutical company; all sources are underground laboratories.
Trenbolone Hexahydrobenzylcarbonate (Parabolan)
Trenbolone hexahydrobenzylcarbonate, marketed as Parabolan, holds a unique place in trenbolone's history as the only ester ever approved and manufactured for human clinical use. Produced by Negma Laboratories in France, it was prescribed for muscle wasting, cachexia, malnutrition, and osteoporosis from 1980 until its voluntary discontinuation in 1997. The hexahydrobenzylcarbonate ester provides a half-life similar to enanthate (approximately 14 days), supporting twice-weekly or even once-weekly injection schedules. While 'Parabolan' remains a widely used label among underground laboratories, no legitimate pharmaceutical product exists today. Any product labeled as Parabolan is a UGL reproduction. Historically, Parabolan was dosed at 76 mg per 1.5 mL ampule (equivalent to 50 mg of trenbolone base per ampule).
Safety
Reported adverse effects, contraindications, and what to monitor on cycle.
Common side effects
- Insomnia and severely disrupted sleep architecture (one of the most universally reported side effects, affecting the majority of users)
- Night sweats, often drenching, requiring sheet changes
- Significantly reduced cardiovascular endurance and aerobic capacity
- Increased aggression, irritability, and shortened temper
- Anxiety and restlessness, particularly at higher doses
- Tren cough: acute, intense coughing fit lasting 30-90 seconds immediately after injection, caused by a small amount of oil entering a blood vessel
- Dark-colored urine (oxidized metabolites; not necessarily indicative of kidney damage but should be monitored)
- Elevated body temperature and increased sweating throughout the day
- Acne and oily skin, particularly on shoulders, back, and chest
- Accelerated hair loss in those genetically predisposed to male pattern baldness
- Profoundly suppressive of natural testosterone production (near-complete HPT axis shutdown)
- Increased heart rate and elevated blood pressure
Rare side effects
- Severe cardiovascular events: significant left ventricular hypertrophy, cardiac fibrosis, and accelerated atherosclerosis with prolonged use
- Prolactin-mediated gynecomastia and nipple discharge (lactation)
- Severe mental health deterioration: paranoia, extreme mood swings, relationship-damaging jealousy and possessiveness
- Sexual dysfunction despite adequate testosterone base, typically prolactin-mediated
- Kidney stress (elevated creatinine, though trenbolone's metabolites can artificially elevate creatinine readings on standard assays)
- Liver enzyme elevation, though less hepatotoxic than oral 17-alpha-alkylated steroids
- Tachycardia and heart palpitations at rest
- Severe digestive issues: acid reflux, reduced appetite at high doses
- Erectile dysfunction persisting after cycle if prolactin is not properly managed
Contraindications
- First steroid cycle or limited anabolic steroid experience (trenbolone is strictly an advanced-only compound)
- Pre-existing cardiovascular disease, cardiomyopathy, or significant cardiac risk factors
- History of mental health conditions: anxiety disorders, depression, bipolar disorder, or psychotic episodes
- Liver disease or significantly elevated liver enzymes
- Kidney disease or impaired renal function
- Uncontrolled hypertension
- Polycythemia (hematocrit above 54% at baseline)
- Prostate cancer or history of hormone-sensitive cancers
- Active or recent substance abuse (trenbolone's psychological effects can exacerbate addictive behaviors)
- Pregnancy or potential for pregnancy in female partners (extremely virilizing compound)
Monitoring
- Complete blood count with hematocrit: baseline and every 4-6 weeks during cycle
- Comprehensive metabolic panel: baseline and every 4-6 weeks (kidney and liver function)
- Lipid panel: baseline and every 4-6 weeks (trenbolone severely impacts HDL/LDL ratio)
- Prolactin: baseline, 3-4 weeks after starting, and as needed based on symptoms
- Estradiol (sensitive assay): at each blood draw to manage aromatization from testosterone base
- Blood pressure: self-monitored at home at least 3x per week throughout cycle
- Cardiac evaluation: echocardiogram recommended before first trenbolone cycle and annually for repeat users
- Fasting glucose and HbA1c: baseline, as trenbolone can influence insulin sensitivity
- Total and free testosterone: to confirm adequate testosterone base
- Kidney function (BUN, creatinine, cystatin C): note that standard creatinine assays can be falsely elevated by trenbolone metabolites; cystatin C provides a more accurate assessment
References
Primary literature and clinical-trial data informing this entry.